Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies15
  • 7D-2.2%
  • 3M6.5%
  • 1Y38.7%
  • YTD8.8%

Last week, the Pharma industry hasn't moved much but GSK is up 4.5% in that time. As for the the longer term, the industry is up 41% over the past 12 months. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026UK£351.5bUK£90.1bUK£15.5b18.9x22.7x3.9x
Sat, 14 Mar 2026UK£342.6bUK£91.2bUK£15.7b21.2x21.8x3.8x
Mon, 09 Feb 2026UK£348.0bUK£89.3bUK£14.7b24x23.6x3.9x
Wed, 07 Jan 2026UK£333.1bUK£89.3bUK£14.6b22x22.8x3.7x
Fri, 05 Dec 2025UK£320.6bUK£89.8bUK£14.7b21x21.9x3.6x
Sun, 02 Nov 2025UK£302.8bUK£89.3bUK£13.9b20.7x21.7x3.4x
Tue, 30 Sep 2025UK£268.6bUK£87.7bUK£11.7b18.6x22.9x3.1x
Thu, 28 Aug 2025UK£282.5bUK£87.5bUK£11.7b21.1x24.2x3.2x
Sat, 26 Jul 2025UK£263.5bUK£86.6bUK£10.7b29.8x24.7x3x
Mon, 23 Jun 2025UK£259.3bUK£86.6bUK£10.6b25.9x24.4x3x
Wed, 21 May 2025UK£262.5bUK£86.8bUK£10.7b26.7x24.6x3x
Fri, 18 Apr 2025UK£252.1bUK£86.6bUK£9.6b26.7x26.3x2.9x
Sun, 16 Mar 2025UK£290.1bUK£87.7bUK£9.6b28.8x30.2x3.3x
Tue, 11 Feb 2025UK£284.5bUK£89.6bUK£9.6b30.5x29.8x3.2x
Thu, 09 Jan 2025UK£229.8bUK£76.1bUK£7.9b31.7x29.2x3x
Sat, 07 Dec 2024UK£227.6bUK£74.8bUK£7.7b32.1x29.6x3x
Mon, 04 Nov 2024UK£236.3bUK£72.6bUK£7.6b31.1x31.2x3.3x
Wed, 02 Oct 2024UK£252.6bUK£71.6bUK£9.0b30.4x28.2x3.5x
Fri, 30 Aug 2024UK£280.8bUK£71.9bUK£9.0b42.1x31.3x3.9x
Sun, 28 Jul 2024UK£259.8bUK£72.2bUK£9.6b34.8x27.2x3.6x
Tue, 25 Jun 2024UK£266.9bUK£71.6bUK£9.6b30.9x27.9x3.7x
Thu, 23 May 2024UK£272.4bUK£71.5bUK£9.6b33.7x28.5x3.8x
Sat, 20 Apr 2024UK£243.1bUK£71.4bUK£9.8b31.9x24.9x3.4x
Mon, 18 Mar 2024UK£236.0bUK£70.4bUK£9.7b32.3x24.3x3.4x
Wed, 14 Feb 2024UK£222.6bUK£69.8bUK£9.6b34.4x23.1x3.2x
Fri, 12 Jan 2024UK£243.0bUK£68.7bUK£10.7b36.8x22.8x3.5x
Sun, 10 Dec 2023UK£226.9bUK£69.4bUK£10.7b33.4x21.1x3.3x
Tue, 07 Nov 2023UK£230.3bUK£70.3bUK£11.0b53.4x21x3.3x
Thu, 05 Oct 2023UK£244.4bUK£70.7bUK£10.4b74.9x23.4x3.5x
Sat, 02 Sep 2023UK£236.9bUK£69.4bUK£10.2b53.5x23.2x3.4x
Mon, 31 Jul 2023UK£241.7bUK£68.1bUK£9.9b52.3x24.5x3.5x
Wed, 28 Jun 2023UK£245.8bUK£67.7bUK£7.9b55.5x31.2x3.6x
Fri, 26 May 2023UK£252.4bUK£68.8bUK£8.0b55.7x31.6x3.7x
Sun, 23 Apr 2023UK£262.0bUK£69.2bUK£6.9b63.2x38.2x3.8x
Price to Earnings Ratio

38.2x


Total Market Cap: UK£262.0bTotal Earnings: UK£6.9bTotal Revenue: UK£69.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.9x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 23.0x which is lower than its 3-year average PE of 25.9x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 9.2% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.19%
Healthcare-1.85%
Pharma-2.23%
Pharma-2.23%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GSK GSKUK£21.310.3%
+UK£212.0m		58.4%PE14.9x
HIK Hikma PharmaceuticalsUK£13.482.6%
+UK£73.5m		-28.7%PE9.8x
HCM HUTCHMED (China)UK£2.201.9%
+UK£34.4m		6.3%PE5.6x
AGY Allergy TherapeuticsUK£0.111.9%
+UK£12.7m		91.2%PS12x
EAH ECO Animal Health GroupUK£1.0412.5%
+UK£7.8m		93.5%PE23.2x

Latest News

GSK
UK£21.31
GSK
7D
0.3%
1Y
58.4%
HCM
UK£2.20
HUTCHMED (China)
7D
1.9%
1Y
6.3%

HCM: Late Stage Oncology Trials And Guidance Will Drive Future Reassessment

Analysts have adjusted their price target on HUTCHMED (China) slightly, linking the change to updated assumptions for revenue growth and profit margins, together with a higher future P/E of 58.40x. What's in the News HUTCHMED issued 2026 guidance for Oncology/Immunology consolidated revenue in a range of US$330m to US$450m, providing a management view of expected business activity for the year (corporate guidance).
EAH
UK£1.04
ECO Animal Health Group
7D
12.5%
1Y
93.5%
STX
UK£0.093
Shield Therapeutics
7D
7.5%
1Y
252.8%

Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17

Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
HLN
UK£3.53
Haleon
7D
-4.3%
1Y
-7.8%

If EPS Growth Is Important To You, Haleon (LON:HLN) Presents An Opportunity

Apr 09
If EPS Growth Is Important To You, Haleon (LON:HLN) Presents An Opportunity
AGY
UK£0.11
Allergy Therapeutics
7D
1.9%
1Y
91.2%
HIK
UK£13.48
Hikma Pharmaceuticals
7D
2.6%
1Y
-28.7%

HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating

Hikma Pharmaceuticals' updated fair value estimate has edged down slightly to £19.02 per share from £19.06. This reflects a series of reduced analyst price targets between £1,600 and £2,000, along with their increased focus on management uncertainty, strategic direction, and a more conservative P/E outlook.
AZN
UK£147.66
AstraZeneca
7D
-3.0%
1Y
44.0%
NFX
UK£0.0017
Nuformix
7D
-10.5%
1Y
28.3%
SAR
UK£0.21
Sareum Holdings
7D
31.3%
1Y
13.5%
POLB
UK£0.046
Poolbeg Pharma
7D
9.5%
1Y
70.4%